immatics biotechnologies GmbH Stock News

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks include high competition in T-cell therapies, potent

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative therapies for cancer patients with high unmet medic

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym

Immatics (IMTX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late Ju

Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX ) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering.

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55.

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.